[Lung Cancer Immunotherapy] Toripalimab (Not Yet Approved in Japan) Combined with Chemotherapy: What the CHOICE-01 Trial Reported

Medical Supporter — Information Notice

This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.

Any specific treatment plan must be assessed by a licensed physician in Japan

In the treatment of metastatic non-small cell lung cancer (NSCLC), immune-chemotherapy combination has become a standard option for first-line treatment. Published in the Journal of Clinical Oncology (JCO), the CHOICE-01 Phase III trial data adds high-quality clinical evidence to this field. The results demonstrate that the novel anti-PD-1 antibody Toripalimab combined with chemotherapy provides long-term survival benefits for a broad population of advanced patients.

1. CHOICE-01 Trial: Comprehensive Improvement in Survival Endpoints

This randomized, double-blind trial enrolled 465 previously untreated advanced patients and compared Toripalimab + chemotherapy versus placebo + chemotherapy.

Key Clinical Data:

Progression-Free Survival (PFS): The combination arm achieved a median PFS of 8.4 months, compared to 5.6 months in the chemotherapy-alone arm, significantly delaying disease progression.
Overall Survival (OS): Results showed a significant benefit trend. In the interim analysis, the median OS in the combination arm had not yet been reached (indicating the majority of patients remained alive), while the control arm was 17.1 months.
Biomarker Findings: The study further found that patients with higher tumor mutational burden (TMB) benefited more significantly from this combination regimen.

2. Safety and Adverse Event Management

The safety profile of Toripalimab combination therapy is comparable to currently known immune-combination regimens:

Common reactions: Primarily chemotherapy-related myelosuppression, as well as immune-related rash or endocrine changes.
Management advantages: Most adverse events were within manageable ranges, and the rate of serious adverse events in the combination arm was essentially equivalent to the chemotherapy arm, indicating that adding the immunotherapy agent did not significantly increase the physical burden on patients.

※ The drug Toripalimab mentioned in this article is currently not approved in Japan. This content is only a summary of published research. To learn about the options that can be considered now, we suggest talking first with your attending physician.

Figure 1